Company intelligence / Profile preview
TA Sciences
New York City, New York, United Statestasciences.com ↗
- Ownership
- Private
- Employees
- ~26
- Development stage
- Other
01
Overview
TA Sciences’ lead compound, TA-65®, has demonstrated in double-blind, placebo-controlled human clinical trials the ability to lengthen telomeres and improve immune health, reduce inflammation following myocardial infarction, and improve cardiovascular markers in metabolic syndrome. The compound is Generally Recognized as Safe and has shown efficacy and safety across more than a decade of clinical data
- Therapeutic areas
- CardiovascularOtherImmunologyMetabolic Disorders
- Modalities
- Small moleculePlant-based compound
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Collaborations with academic centers (e.g., University of Texas Southwestern, Newcastle University, Harvard University)
Beyond the preview
Go deeper on TA Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TA Sciences.